IMUNON (IMNN)

Executive Summary

IMUNON is a clinical-stage biotechnology company developing novel DNA-based immunotherapies and vaccines using its proprietary non-viral delivery platforms, TheraPlas™ and PlaCCine. The company's lead candidate, IMNN-001, is an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, designed to induce potent anti-tumor immune responses. IMNN-001 is currently being evaluated in a Phase 3 trial (OVATION 3) for advanced epithelial ovarian cancer, which began recruiting in July 2025 and is expected to complete in 2032, with interim analyses possible in the coming years. Additionally, a Phase 1/2 trial (NCT05739981) combining IMNN-001 with paclitaxel, carboplatin, and bevacizumab in ovarian cancer is actively enrolling. IMUNON's platform also holds potential for infectious disease vaccines, though oncology remains the primary focus. The company's success hinges on the clinical progress of IMNN-001 and the broader utility of its delivery platforms.

Upcoming Catalysts (preview)

• Q2 2027Phase 3 OVATION 3 Trial Interim Data for IMNN-001 in Ovarian Cancer50% success
• Q4 2026Enrollment Completion or Update for Phase 1/2 Trial of IMNN-001 Combination70% success
• Q1 2027Potential FDA Meeting or Guidance on Accelerated Approval Path40% success